alexa
Reach Us +1-947-333-4405
Editor - Abhishek Srivastava | National Cancer Institute | 18598

Journal of Clinical & Experimental Neuroimmunology
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Abhishek Srivastava

Abhishek Srivastava
Abhishek Srivastava
National Cancer Institute
National Institutes of Health
USA

Biography

Dr. Abhishek Srivastava is currently working at National Cancer Institute at National Institutes of Health (NIH) where his translational research involves the development of new immunotherapy strategies against advanced cancers. He received his PhD from University of Louisville, School of Medicine, USA. Dr. Srivastava also brings the pharmaceutical industry experience as he worked as Research Investigator to support the innovative immuno-oncology drug discovery pipeline for Bristol-Myers Squibb. Dr. Srivastava authored 30 plus research articles which include abstracts, book chapter and expert opinions.

Research Interest

Dr. Abhishek Srivastava’s main research interest is the utilization of immune-modulating agents for the improvement of current tumor-specific vaccines and adoptive T cell therapy (ACT). His research primarily focus on the application of multiple cellular and molecular approaches including preclinical in vitro experimentation, in vivo murine models, and innovative human clinical trials to evaluate and explore the mechanism of these immunomodulators as an effective immunotherapy for advanced cancers.

Certificate

Certificate

Global Speakers in the subject

Global Experts in the subject

Leave Your Message 24x7
Top